Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy

R. M. Sherry, H. I. Pass, S. A. Rosenberg, J. C. Yang

Research output: Contribution to journalArticle

Abstract

Thirty-one patients with disseminated melanoma or renal cell cancer (RCC) who had a limited relapse or persistent disease after a partial or complete response to interleukin-2 (IL-2)-based immunotherapy underwent resection of progressing tumors or residual sites of disease. There were no surgery- related deaths. The median time to disease progression after resection for patients with RCC (n = 16) and melanoma (n = 15) was 11 and 5 months, respectively. All patients with melanoma had tumor progression within 10 months of surgery. Seven of 16 patients with RCC were free of tumor progression 4 to 44 months after surgery. Three of 12 patients with RCC rendered disease-free by surgery remain disease-free after 2 years. These data suggest that surgical resection is a reasonable option in selected patients who have a relapse after responding to IL-2-based immunotherapy. Although this retrospective study could not determine the relative survival benefits of surgery and immunotherapy, it showed that resection of metastatic disease after a response to immunotherapy can result in significant disease- free survival in patients with RCC but not melanoma.

Original languageEnglish (US)
Pages (from-to)1850-1855
Number of pages6
JournalCancer
Volume69
Issue number7
StatePublished - 1992
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Interleukin-2
Melanoma
Recurrence
Residual Neoplasm
Disease-Free Survival
Disease Progression
Neoplasms
Retrospective Studies
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sherry, R. M., Pass, H. I., Rosenberg, S. A., & Yang, J. C. (1992). Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer, 69(7), 1850-1855.

Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. / Sherry, R. M.; Pass, H. I.; Rosenberg, S. A.; Yang, J. C.

In: Cancer, Vol. 69, No. 7, 1992, p. 1850-1855.

Research output: Contribution to journalArticle

Sherry, RM, Pass, HI, Rosenberg, SA & Yang, JC 1992, 'Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy', Cancer, vol. 69, no. 7, pp. 1850-1855.
Sherry, R. M. ; Pass, H. I. ; Rosenberg, S. A. ; Yang, J. C. / Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. In: Cancer. 1992 ; Vol. 69, No. 7. pp. 1850-1855.
@article{e423598485ad4c418d56e18e5b613a5f,
title = "Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy",
abstract = "Thirty-one patients with disseminated melanoma or renal cell cancer (RCC) who had a limited relapse or persistent disease after a partial or complete response to interleukin-2 (IL-2)-based immunotherapy underwent resection of progressing tumors or residual sites of disease. There were no surgery- related deaths. The median time to disease progression after resection for patients with RCC (n = 16) and melanoma (n = 15) was 11 and 5 months, respectively. All patients with melanoma had tumor progression within 10 months of surgery. Seven of 16 patients with RCC were free of tumor progression 4 to 44 months after surgery. Three of 12 patients with RCC rendered disease-free by surgery remain disease-free after 2 years. These data suggest that surgical resection is a reasonable option in selected patients who have a relapse after responding to IL-2-based immunotherapy. Although this retrospective study could not determine the relative survival benefits of surgery and immunotherapy, it showed that resection of metastatic disease after a response to immunotherapy can result in significant disease- free survival in patients with RCC but not melanoma.",
author = "Sherry, {R. M.} and Pass, {H. I.} and Rosenberg, {S. A.} and Yang, {J. C.}",
year = "1992",
language = "English (US)",
volume = "69",
pages = "1850--1855",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy

AU - Sherry, R. M.

AU - Pass, H. I.

AU - Rosenberg, S. A.

AU - Yang, J. C.

PY - 1992

Y1 - 1992

N2 - Thirty-one patients with disseminated melanoma or renal cell cancer (RCC) who had a limited relapse or persistent disease after a partial or complete response to interleukin-2 (IL-2)-based immunotherapy underwent resection of progressing tumors or residual sites of disease. There were no surgery- related deaths. The median time to disease progression after resection for patients with RCC (n = 16) and melanoma (n = 15) was 11 and 5 months, respectively. All patients with melanoma had tumor progression within 10 months of surgery. Seven of 16 patients with RCC were free of tumor progression 4 to 44 months after surgery. Three of 12 patients with RCC rendered disease-free by surgery remain disease-free after 2 years. These data suggest that surgical resection is a reasonable option in selected patients who have a relapse after responding to IL-2-based immunotherapy. Although this retrospective study could not determine the relative survival benefits of surgery and immunotherapy, it showed that resection of metastatic disease after a response to immunotherapy can result in significant disease- free survival in patients with RCC but not melanoma.

AB - Thirty-one patients with disseminated melanoma or renal cell cancer (RCC) who had a limited relapse or persistent disease after a partial or complete response to interleukin-2 (IL-2)-based immunotherapy underwent resection of progressing tumors or residual sites of disease. There were no surgery- related deaths. The median time to disease progression after resection for patients with RCC (n = 16) and melanoma (n = 15) was 11 and 5 months, respectively. All patients with melanoma had tumor progression within 10 months of surgery. Seven of 16 patients with RCC were free of tumor progression 4 to 44 months after surgery. Three of 12 patients with RCC rendered disease-free by surgery remain disease-free after 2 years. These data suggest that surgical resection is a reasonable option in selected patients who have a relapse after responding to IL-2-based immunotherapy. Although this retrospective study could not determine the relative survival benefits of surgery and immunotherapy, it showed that resection of metastatic disease after a response to immunotherapy can result in significant disease- free survival in patients with RCC but not melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0026587391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026587391&partnerID=8YFLogxK

M3 - Article

C2 - 1551067

AN - SCOPUS:0026587391

VL - 69

SP - 1850

EP - 1855

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -